Protalix BioTherapeutics Cash from Financing (TTM) Analysis

Protalix BioTherapeutics Inc (PLX)

1.14 0.00 (0.00%) USD | NYAM | Apr 17, 16:00

1.14 0.00 (0.00%) After-Hours: 20:00

Cash from Financing (TTM) Chart

Historical Cash from Financing (TTM) Data

View and export this data back to 1999. Upgrade now.

Date	Value
December 31, 2023	24.67M
September 30, 2023	28.74M
June 30, 2023	30.26M
March 31, 2023	22.47M
December 31, 2022	8.238M
September 30, 2022	0.117M
June 30, 2022	-27.39M
March 31, 2022	-30.04M
December 31, 2021	12.08M
September 30, 2021	20.78M
June 30, 2021	51.24M
March 31, 2021	49.97M
December 31, 2020	46.47M
September 30, 2020
June 30, 2020
March 31, 2020
December 31, 2019
September 30, 2019
June 30, 2019
March 31, 2019
December 31, 2018
September 30, 2018
June 30, 2018
March 31, 2018
December 31, 2017	-1.419M

Date	Value
September 30, 2017	18.28M
June 30, 2017	8.734M
March 31, 2017	12.97M
December 31, 2016
September 30, 2016
June 30, 2016
March 31, 2016
December 31, 2015
September 30, 2015
June 30, 2015
March 31, 2015
December 31, 2014	0.046M
September 30, 2014	-0.025M
June 30, 2014	66.89M
March 31, 2014	66.92M
December 31, 2013
September 30, 2013
June 30, 2013
March 31, 2013
December 31, 2012	26.56M
September 30, 2012	26.44M
June 30, 2012	26.58M
March 31, 2012	25.56M
December 31, 2011	20.93M
September 30, 2011	21.26M

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (TTM) Range, Past 5 Years

-30.04M

Minimum

Mar 2022

51.24M

Maximum

Jun 2021

18.28M

Average

22.47M

Median

Mar 2023

Cash from Financing (TTM) Benchmarks